07:24 AM EDT, 06/03/2024 (MT Newswires) -- GSK (GSK) shares were down 9% in recent Monday premarket trading after a Delaware court ruled Friday that the company should face trials over allegations that its heartburn treatment Zantac causes cancer.

"The scientific consensus is that there is no consistent or reliable evidence that ranitidine (Zantac) increases the risk of any cancer," GSK said in a statement responding to the ruling. The company said it will immediately seek an appeal.

GSK said the latest Delaware decision contradicts a ruling from a federal court, which dismissed similar claims against Zantac in 2022.

In addition to an appeal, GSK said it plans to file motions for dismissal pressing additional defenses, severance of cases, and proof-of-use by claimants.

Price: 40.82, Change: -3.95, Percent Change: -8.82